The biopharmaceutical sector has once again captured the spotlight in the financial markets. According to data from Gongmu Paipai.com, between August 3 and August 9, public offering institutions conducted 104 research visits to the biopharmaceutical industry, ranking it first among all Shenwan first-level industries and surpassing the electronics sector, which had previously drawn sustained attention. On the capital front, Wind data reveals that in the first seven months of this year, innovative drug-related ETFs saw a combined net inflow of over 41 billion yuan. This steady stream of capital reflects a rapidly escalating market interest in the pharmaceutical sector, particularly the innovative drug track.
On the news front, the innovative drug sector has recently been flooded with positive developments. Aggregating the views of multiple institutions, the innovative drug sector appears promising, driven by the convergence of earnings realization, capital cycle dynamics, and policy support.
Mid-Year Earnings Reports Centralize, Shifting the Industry from Valuation Speculation to Earnings Momentum
According to statistics from Qiyeyujingtong, as of August 6, 105 pharmaceutical listed companies had disclosed their first-half 2026 earnings forecasts, with an industry-wide positive outlook rate of 46.7% and combined profits of 19.82 billion yuan, a remarkable year-on-year surge of 103.6%. The enhanced commercialization capabilities of innovative drug companies stand out as a core highlight, with several leading pharmaceutical firms witnessing robust sales growth of key products, narrowing losses, and some even marking a definitive turning point toward profitability.
Analysts suggest that leading domestic innovative drug companies have validated the industry's recovery through three dimensions: CXO orders, innovative drug product sales, and global commercialization milestones. This confirms that the sector's prosperity is gradually transmitting from BD transactions and valuation expectations to revenue, profits, and cash flow. In areas such as bispecific antibodies and ADCs, a platform-based advantage has been established, and mature technology platforms are expected to continuously incubate and iterate pipelines, driving demand recovery across the industry chain. Consequently, the sector's valuation framework is poised to shift from "expectation speculation" to "earnings-driven" fundamentals.
Financing Sentiment Recovers in Domestic and Global Biopharma, Signaling a Potential Upward Turn in the Capital Cycle
According to Pharmcube data, the first half of 2026 witnessed a significant recovery in primary market financing for biopharmaceuticals both domestically and internationally, injecting robust momentum into the industry. In China, the healthcare sector completed 814 financing deals totaling 72.6 billion yuan, a year-on-year increase of 41.7%, with innovative drug financing reaching 41.8 billion yuan, soaring 79.1% year-on-year. Globally, innovative drug financing also showed vitality, with 505 financing events in the first half, aggregating $26.8 billion, a 58.5% year-on-year growth. Concurrently, out-licensing deals for Chinese new drugs have been exceptionally active, with 210 transactions in the first half, reaching a total value of $105.1 billion, up 73% year-on-year. Analysts note that the resurgence of financing activity in the biotech sector, coupled with the ongoing boom in Chinese innovative drug out-licensing, will accelerate global new drug R&D efforts, and the domestic CXO industry chain is well-positioned to benefit from this industrial dividend.
Sustained Policy Support and Cutting-Edge Technologies Expand Long-Term Growth Prospects
The continuous optimization of the policy environment and a dense pipeline of R&D breakthroughs have solidified the foundation for the industry's long-term development. In terms of policy support, the National Medical Products Administration issued a policy in July that includes eligible CGT drugs in a 30-day priority review channel for innovative drug clinical trials, expediting the deployment of frontier therapies. In August, Beijing released a document outlining nine supportive measures covering the entire CGT industry chain across five dimensions: innovation, clinical practice, platforms, regulation, and industry. Research reports indicate that CAR-T cell therapy offers a potentially transformative approach to combating currently incurable cancers, and with policy backing, the commercialization of CAR-T treatments may be on the verge of a breakthrough.
On the R&D front, preliminary statistics show that 43 domestic innovative drug studies have been selected for oral presentations at the upcoming ESMO 2026 conference, with bispecific antibodies and ADCs remaining hot areas. As frontier fields such as cell therapy and AI-driven drug development continue to advance, more options for solid tumor treatment will emerge. The subsequent release of ESMO conference abstracts and the formal sessions are expected to further validate the clinical progress and out-licensing potential of domestic innovative drugs.
Some institutions argue that, viewed through the lens of multinational pharmaceutical pipeline streamlining and China's BD out-licensing trends, Chinese drug innovation has become an indispensable part of global innovation. It is progressively transitioning from a follower to a pioneer, with heightened demand for new target validation boosting the prosperity of early-stage research-related industry chains. Looking ahead to the second half of 2026, with shifting market style preferences, attention on innovative drugs has markedly increased, and the trajectory of later-stage key clinical data and commercialization outcomes will ultimately determine value direction.
For retail investors, directly researching individual company pipelines and financial details presents a high barrier. Leveraging index-based investment tools may offer a more efficient and diversified approach to managing risk. For those optimistic about the long-term value of the innovative drug industry, within their own risk tolerance, options such as the Hong Kong Innovative Drug ETF Yinhua (159567) and its feeder funds (Class A: 023929, Class C: 023930), as well as the Innovative Drug ETF Yinhua (159992) and its feeder funds (Class A: 012781; Class C: 012782), could be considered to capture the benefits of the local innovative drug industry upgrade.
Risk Disclosure
Investment involves risk, and caution is advised. Funds are long-term investment tools whose primary function is to diversify investments and reduce the specific risks associated with investing in a single security. Funds differ from financial instruments like bank deposits that provide fixed income expectations. When purchasing fund products, you may either share in the investment returns generated by the fund based on your held shares or bear the losses incurred by the fund's investments. Before making any investment decisions, please carefully read the fund contract, fund prospectus, fund product summary, and other legal documents, as well as this risk disclosure statement. Fully understand the risk-return characteristics and product features of the fund, and carefully consider all risk factors. Make rational judgments and cautious investment decisions based on your own investment objectives, horizon, experience, asset status, and risk tolerance, and in light of product understanding and sales suitability opinions.
According to relevant laws and regulations, Yinhua Fund Management Co., Ltd. makes the following risk disclosures: First, based on different investment targets, funds are categorized into stock funds, hybrid funds, bond funds, money market funds, fund of funds, commodity funds, and other types. Investing in different types of funds will yield different return expectations and entail varying degrees of risk. Generally, the higher the expected return, the greater the risk you assume. Second, funds may face various risks during operation, including market risk, as well as the fund's own management, technical, and compliance risks. Massive redemption risk is a unique risk of open-end funds, meaning that if net redemption requests exceed a certain percentage of total fund shares on a single open day (10% for open-end funds, 20% for periodically open funds, except for special products specified by the CSRC), you may be unable to redeem all requested fund shares in a timely manner, or redemption payments may be delayed. Third, you should fully understand the difference between regular fixed-amount fund investment and savings methods like installment deposits. Fixed-amount investment is a simple way to guide long-term investment and average investment costs, but it does not avoid the inherent risks of fund investment, does not guarantee investor returns, and is not an equivalent savings alternative. Fourth, special product risk disclosure: 1. Investors should be aware of the risks of underlying index fluctuations and the specific risks of ETF investments. Feeder funds invest in underlying ETFs, and investors should be aware of the specific risks of feeder fund investments, including tracking deviation risk, performance divergence risk from the target ETF, other risks of investing in the target ETF, and risks of tracking error control not meeting agreed targets. 2. The Hong Kong Innovative Drug ETF Yinhua and its feeder funds may invest in stocks under the Stock Connect mechanism, facing specific risks arising from differences in the investment environment, targets, market systems, and trading rules under the Stock Connect framework. Fifth, the fund manager promises to manage and use fund assets with honesty, good faith, diligence, and responsibility but does not guarantee profitability or minimum returns. Past performance and net value levels do not indicate future performance, and the performance of other funds managed by the manager does not constitute a guarantee of this fund's performance. Yinhua Fund Management Co., Ltd. reminds you of the "buyer beware" principle. After making investment decisions, the investment risks arising from fund operations and net value changes are borne by you. The fund manager, custodian, sales institutions, and related parties make no promises or guarantees on investment returns. Sixth, this fund is raised by Yinhua Fund Management Co., Ltd. in accordance with relevant laws and regulations and has been registered with the approval of the China Securities Regulatory Commission (CSRC). The fund contract, prospectus, and product summary have been publicly disclosed on the CSRC fund electronic disclosure website at http://eid.csrc.gov.cn/fund and the manager's website at www.yhfund.com.cn. The CSRC's registration does not constitute a substantive judgment or guarantee of the fund's investment value, market prospects, or returns, nor does it indicate that investing in the fund is risk-free.